Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYN002 transdermal gel in children and adolescents with Fragile X syndrome
ACTRN12617000150347Phase 2Active, not recruiting
- Sponsor
- Zynerba Pharmaceuticals
- Start
- Mar 2017
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Zygel in Fragile X syndrome (FXS), sponsored by Zynerba Pharmaceuticals. Primary endpoint: Safety and tolerability assessed by change from screening in ADAMS total score. Started Mar 2017; status: active, not recruiting.
02
Drugs
Zygel
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on ACTRN12617000150347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000150347.